Traditional Naturopath Shares Inspiring Journey to Healing from Addiction, Chronic Illness in Debut Memoir
January 19, 2021 07:00 ET
|
Balboa Press
GIBSON, La., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Author and traditional naturopath Michelle L. Potter has published her uplifting memoir that invites readers to share in Potter’s persistence and...
Seven Leading Non-Profit Providers Leverage Experience Treating Patients with Advanced Illness at Home for New, Unique Medicare Care Model
December 08, 2020 19:12 ET
|
Capital Caring
Falls Church, Virginia, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Seven of the nation’s largest and well-known non-profit advanced illness providers have formed Advanced Illness Partners (AIP) to...
Capital Caring Health Partners with Six Leading Non-Profit Providers to Leverage Experience Treating Patients with Advanced Illness at Home
December 07, 2020 16:59 ET
|
Capital Caring
Falls Church, Virginia, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Capital Caring Health has joined forces with six of the nation’s largest and well-known non-profit advanced illness providers to form...
Witness a true story of long-term suffering with chronic illness, addiction and Lyme disease transformed by the will to live
November 10, 2020 01:27 ET
|
Balboa Press
GIBSON, La., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Despite the debilitating pain, discomfort and mysterious symptoms that Michelle L. Potter had since childhood, doctors kept telling that there is...
Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma
June 05, 2020 01:15 ET
|
Novartis International AG
Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving...
Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine
April 16, 2020 01:15 ET
|
Novartis International AG
Real-world evidence supports benefits seen in Aimovig clinical trials Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc and...
Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran
January 06, 2020 12:05 ET
|
Novartis International AG
Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL...
Novartis completes tender offer for all outstanding shares of The Medicines Company
January 06, 2020 01:00 ET
|
Novartis International AG
Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger...
Inspire’s Health Profiles Identifies the Insights of Patients to Unlock Research Gaps
December 13, 2018 08:00 ET
|
Inspire
ARLINGTON, Va., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Inspire, the leading healthcare social network for patients and caregivers, is offering new opportunities for academic research partners to...
Lyfebulb and UnitedHealth Group Announce Winners of the 2018 Innovation Challenge for Patient Entrepreneurs
July 26, 2018 09:00 ET
|
Lyfebulb
MINNETONKA, Minn. and NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Lyfebulb LLC and UnitedHealth Group (NYSE:UNH) have selected Jon Margalit of Complete Start as the winner of the first-ever Lyfebulb...